Statins are hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors that inhibit endogenous cholesterol synthesis, up-regulate LDL receptors, and accelerate the clearance of circulating LDL particles, thereby reducing plasma levels. LDL levels. It is currently widely used clinically to regulate blood lipids, and is the first choice for the treatment of hyperlipidemia patients with elevated cholesterol. Studies have confirmed that the lipid-lowering efficacy and the risk of adverse events produced by different individuals taking statins are directly related to the ApoE and SLCO1B1 gene polymorphisms in the body. ApoE gene is an encoding gene in the apolipoprotein family involved in lipid metabolism. Different ApoE genotypes lead to differences in the lipid-lowering effect of statins among individuals; while the SLCO1B1 gene is directly involved in the metabolism of statins, and SLCO1B1 gene polymorphisms lead to differences in the risk of adverse drug reactions to statins in different individuals.

This kit detects the polymorphisms of ApoE gene T388C, C526T locus and SLCO1B1 gene T521C locus to determine the statin metabolism and lipid-lowering efficacy of the tested population, so as to correctly select the drug and adjust the drug dose reasonably to ensure the efficacy of the drug. Reduce the risk of adverse drug reactions.